A Phase 3 interventional study of Raphamin and Placebo in Acute Respiratory Viral Infection, sponsored by Materia Medica Holding. Completed at 29 sites in Russian Federation. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Materia Medica Holding · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The multicenter double-blind placebo-controlled randomized in parallel-group. The objective of this study is to evaluate efficacy and safety of Raphamin in the treatment of acute respiratory viral infection (ARVI) in children aged 12-18 years old.
Design: a multicenter, double-blind, placebo-controlled, parallel-group randomized clinical trial.
The study will enroll outpatient subjects of either gender aged 12-18 old years with clinical manifestations of acute respiratory viral infection (ARVI) within the first days after the onset of the disease. The patients will be recruited during seasonal ARVI morbidity. Collection of history, thermometry, objective examination, laboratory tests, recording concomitant therapy will be made after parent/adoptive parent signing information sheet and informed consent form for the child participation in the clinical study, for children ≥14 years old after signing patient information sheet and informed consent form for children ≥14 years old to participate in the clinical study. The severity of ARVI symptoms will be evaluated with a 4-point scale.
The nasopharyngeal swabs for PCR diagnosis and verification of respiratory viruses will be performed prior to therapy to confirm the viral etiology of ARVI. To rule out the infection caused by the new coronavirus COVID-19 (Coronavirus disease 2019), a rapid test for SARS-CoV-2 antigen will be made. In case of a positive SARS-CoV-2 test, the physician will act in accordance with the current version of the RF MoH Temporary methodological recommendations "Prevention, diagnosis, and therapy of new coronavirus infection (COVID-19)".
If a patient meets all inclusion criteria and does not have any exclusion criteria, at Visit 1 (Day 1), he/she will be randomized into one of two groups: patients of group 1 will take Raphamin according to the dosage regimen for 5 days; patients of group 2 will take Placebo using Raphamin 5-day regimen.
The study will use an electronic patient diary (EPD) for recording morning and evening axillary body temperature (using a classic mercury-free thermometer) and disease symptoms (Symptom Severity Score). Besides, antipyretic dosing (if applicable) and any deterioration in a patient's condition (if applicable, for safety evaluation/AE documentation) will also be recorded in a patient diary. The investigator will provide instructions on filling the diary. At Visit 1 the parent/adoptive parent together with an investigator will record ARVI symptom severity and body temperature in the diary.
Patients will be observed for 14 days (screening, randomization - up to 1 day, treatment period - 5 days, follow-up - up to 2 days; deferred "phone visit" - day 14).
During the treatment and follow-up period the patients/physicians will make 3 visits and the fourth "phone visit" will be scheduled additionally: 1) visits by physician/patient - on Days 1, 5, and 7 (Visits 1, 2, and 3) - in a study center or at home; 2) "phone visit" (Visit 4) - on Day 14.
At Visits 2 and 3, the investigator will perform an objective examination, document changes in the symptoms and concomitant medications, and check patient diaries. At Visit 3 laboratory tests will be performed and compliance will be checked.
"Phone visit" will be performed to interview parents/adoptive parents about the patient's condition, presence/absence of secondary bacterial/viral complications, and use of antibiotics.
During the study, symptomatic therapy and therapy for their co-morbidities are allowed with the exception of the drugs indicated in the section "Prohibited Concomitant Treatment".
Materia Medica Holding is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tablet for oral use.
Drug: Raphamin
Tablet for oral use.
Drug: Placebo
Oral administration - not with food. Keep the tablet in the mouth until it is completely dissolved. On the 1st day of treatment, 8 tablets are taken according to the following scheme: 1 tablet every 30 minutes in the first 2 hours (a total of 5 tablets in 2 hours), then during the same day, take another 1 tablet 3 times at regular intervals. On the 2nd day and then take 1 tablet 3 times a day. The duration of treatment is 5 days.
Oral administration - not with food. Placebo using Raphamin scheme.
Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).
Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
Time frame: 14 days of observation
Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).
The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.
Time frame: Day1 through Day6 of the treatment and observation
Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
Time frame: 14 days of observation
Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
Time frame: 14 days of observation
Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).
Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
Time frame: 14 days of observation
Dosing Frequency of Antipyretics.
Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.
Time frame: 3 days of therapy
Percentage of Patients Reporting Worsening of Illness.
Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.
Time frame: Day 4 through day 14 of the treatment and observation period
Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.
1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records.
Time frame: 14 days of observation
Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).
The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.
Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).
Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).
Time frame: Day 1 through day 7 of the treatment and observation period.
Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.
Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.
Time frame: Day 1 through day 7 of the treatment and observation period.
| Milestone | Raphamin | Placebo |
|---|---|---|
| Started | 206 | 214 |
| Completed | 199 | 205 |
| Not completed | 7 | 9 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Incorrect inclusion ineligible patient | 3 | 4 |
Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
| day | Raphamin | Placebo |
|---|---|---|
| Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)). | 3.3 ± 1.7 | 4.4 ± 2.6 |
The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score). TSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules: if temp \<= 37.3 then score = 0 (none) if 37.3 \< temp \<= 38.0 then score = 1 (mild) if 38.0 \< temp \<= 39.0 then score = 2 (moderate) if 39.0 \< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.
| scores on a scale*days | Raphamin | Placebo |
|---|---|---|
| Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed), AUC score | 44.6 ± 23.8 | 46.9 ± 24.3 |
| Severity of ARVI (PCR-confirmed), AUC score | 48.3 ± 25.2 | 53.6 ± 25.6 |
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
| Participants | Raphamin | Placebo |
|---|---|---|
| Day 2 | 24 | 16 |
| Day 3 | 64 | 46 |
| Day 4 | 96 | 94 |
| Day 5 | 149 | 136 |
| Day 6 | 174 | 162 |
| Day 7 | 191 | 181 |
ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
| day | Raphamin | Placebo |
|---|---|---|
| Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed). | 3.4 ± 1.8 | 3.9 ± 2.4 |
Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection. ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from "0" to "42". The TSS higher score is the worse outcome.
| Participants | Raphamin | Placebo |
|---|---|---|
| Day 2 | 16 | 4 |
| Day 3 | 36 | 16 |
| Day 4 | 59 | 39 |
| Day 5 | 95 | 64 |
| Day 6 | 107 | 77 |
| Day 7 | 119 | 89 |
Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.
| number of doses | Raphamin | Placebo |
|---|---|---|
| Day 1 | 0.43 ± 0.72 | 0.39 ± 0.72 |
| Day 2 | 0.22 ± 0.61 | 0.25 ± 0.66 |
| Day 3 | 0.09 ± 0.38 | 0.07 ± 0.31 |
Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.
| Participants | Raphamin | Placebo |
|---|---|---|
| Percentage of Patients Reporting Worsening of Illness. | 1 | 0 |
1. The intensity (severity) of adverse events. 2. Causal relationship of AEs to the sudy drug. 3. Outcome of AEs. Based on medical records.
| number of cases | Raphamin | Placebo |
|---|---|---|
| Severity/Mild | 2 | 6 |
| Severity/Moderate | 5 | 0 |
| Causal relationship/Not connected | 7 | 6 |
| Outcome/Recovery | 6 | 5 |
| Outcome/Unknown | 1 | 1 |
The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).
| beats per minute | Raphamin | Placebo |
|---|---|---|
| Visit 1 | 87.1 ± 11.4 | 87.2 ± 10.6 |
| Visit 2 | 77.9 ± 7.1 | 78.1 ± 7.2 |
| Visit 3 | 76.3 ± 7.0 | 76.7 ± 6.8 |
Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).
| breaths per minute | Raphamin | Placebo |
|---|---|---|
| Visit 1 | 20.8 ± 3.3 | 20.7 ± 2.8 |
| Visit 2 | 18.4 ± 1.9 | 18.6 ± 1.7 |
| Visit 3 | 18.0 ± 1.7 | 18.2 ± 1.7 |
Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).
| mmHg | Raphamin | Placebo |
|---|---|---|
| Visit 1/Systolic blood pressure | 112 ± 9.9 | 112 ± 8.9 |
| Visit 2/Systolic blood pressure | 111 ± 9.8 | 112 ± 8.7 |
| Visit 3/Systolic blood pressure | 111 ± 10.2 | 111 ± 9.4 |
| Visit 1/Diastolic blood pressure | 70.0 ± 5.7 | 69.8 ± 5.8 |
| Visit 2/Diastolic blood pressure | 69.7 ± 5.7 | 69.5 ± 5.4 |
| Visit 3/Diastolic blood pressure | 69.6 ± 5.7 | 69.4 ± 5.9 |
Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.
| Participants | Raphamin | Placebo |
|---|---|---|
| Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings. | 1 | 0 |
Collected over Registration of AEs begins after the first dose of study drug and continues throughout the entire period of study therapy - 14 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Raphamin | 0/206 (0%) | 1/206 (0.5%) | 6/206 (2.9%) |
| Placebo | 0/214 (0%) | 0/214 (0%) | 5/214 (2.3%) |
| Event | Raphamin | Placebo |
|---|---|---|
| Worsening fluInfections and infestations | 1/206 | 0/214 |
| Event | Raphamin | Placebo |
|---|---|---|
| Bacterial superinfectionInfections and infestations | 1/206 | 0/214 |
| Viral upper respiratory tract infectionInfections and infestations | 1/206 | 0/214 |
| Increased percentage of monocytesInvestigations | 1/206 | 0/214 |
| DizzinessNervous system disorders | 1/206 | 0/214 |
| Loss of consciousnessNervous system disorders | 1/206 | 0/214 |
| PallorVascular disorders | 1/206 | 0/214 |
| FluInfections and infestations | 1/206 | 1/214 |
| AdenoiditisInfections and infestations | 0/206 | 1/214 |
| Coronavirus infection COVID-19Infections and infestations | 0/206 | 1/214 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/206 | 1/214 |
| Age, Continuous(years) | Raphamin | Placebo | Total |
|---|---|---|---|
| Mean | 14.3 ± 1.7 | 14.2 ± 1.7 | 14.2 ± 1.7 |
| Age, Customized(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| 12 to 18 years | 199 | 205 | 404 |
| Sex: Female, Male(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Female | 100 | 107 | 207 |
| Male | 99 | 98 | 197 |
| Race and Ethnicity Not Collected(Participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(participants) | Raphamin | Placebo | Total |
|---|---|---|---|
| Russia | 199 | 205 | 404 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2021 to primary completion in Jul 2023, 26 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MMH-407